Trial watch: Peptide vaccines in cancer therapy.

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22

Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21

Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04

Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

Current trends of anticancer immunochemotherapy. Oncoimmunology (2013) 0.91

Victories and deceptions in tumor immunology: Stimuvax(®) Oncoimmunology (2013) 0.91

Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol (2013) 0.90

Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89

Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells. J Biol Chem (2015) 0.87

Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86

Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) (2013) 0.85

Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84

Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci (2015) 0.84

Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83

Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J (2014) 0.82

Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80

Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice. Mar Drugs (2015) 0.78

Rejuvenated T cells attack old tumors. Oncoimmunology (2013) 0.76

Helper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L. Oncoimmunology (2013) 0.76

Nanocarrier-based immunotherapy in cancer management and research. Immunotargets Ther (2014) 0.76

Use of adjuvants for immunotherapy. Hum Vaccin Immunother (2017) 0.75

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncoimmunology (2017) 0.75

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08

Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96

Towards a network theory of the immune system. Ann Immunol (Paris) (1974) 16.43

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28

Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57

The danger model: a renewed sense of self. Science (2002) 13.85

Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet (2009) 13.51

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009) 11.63

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46

FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 8.73

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28

Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 5.31

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15

Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer (2010) 4.99

Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01

A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 3.84

Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity (2007) 3.84

The biochemistry of somatic hypermutation. Annu Rev Immunol (2008) 3.78

Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78

Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med (2007) 3.77

Immune therapy for cancer. Annu Rev Immunol (2009) 3.71

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00

"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80

Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67

Immunotherapy: past, present and future. Nat Med (2003) 2.62

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin (2009) 2.51

The confirmation and maintenance of smallpox eradication. N Engl J Med (1980) 2.46

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA (1986) 2.26

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19

Overexpression of folate binding protein in ovarian cancers. Int J Cancer (1997) 2.13

Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 2.09

Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A (1972) 2.09

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03

Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer (2011) 2.02

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood (2009) 1.90

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res (2007) 1.80

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res (2001) 1.79

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

The testis in immune privilege. Immunol Rev (2006) 1.77

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation (2009) 1.77

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75

T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74

Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72

The makings of a tumor rejection antigen. Immunity (1999) 1.71

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65

Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) (2005) 1.65

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58

MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer (2009) 1.53

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51

Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci (2009) 1.49

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44

Effector mechanisms in allograft rejection. Annu Rev Immunol (1986) 1.43

Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42

EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res (2004) 1.39

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer (2011) 1.38

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36

Immunogenicity signals 1,2,3 ... and 0. Immunol Today (1989) 1.35

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A (2008) 1.34

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother (2004) 1.34

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17

Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70

Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62

Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61

Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56

Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56